Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Robert J. Kreitman

Bldg 5124b

9000 Rockville Pike

Bethesda

MD 20892;

[email]@mail.nih.gov

Name/email consistency: high

[Claim this account]

Affiliations

Bldg 5124b, 9000 Rockville Pike, Bethesda, MD 20892;. 2012
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, USA. 2009 - 2011
Laboratory of Molecular Biology, Laboratory of Clinical Pathology, and Medicine Branch, National Cancer Institute, USA. 1999 - 2009
Division of Cancer Biology, National Institutes of Health, 9000 Rockville, Bethesda, USA. 2003
National Institutes of Health, Bethesda, MD 20892-4255, USA. 2002
National Cancer Institute, NIH, Clinical Immunotherapy Section, Laboratory of Molecular Biology, USA. 2001

References

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. Kreitman, R.J., Tallman, M.S., Robak, T., Coutre, S., Wilson, W.H., Stetler-Stevenson, M., Fitzgerald, D.J., Lechleider, R., Pastan, I. J. Clin. Oncol. (2012) [Pubmed]
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Kreitman, R.J., Arons, E., Stetler-Stevenson, M., Fitzgerald, D.J., Wilson, W.H., Pastan, I. Leuk. Lymphoma (2011) [Pubmed]
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. Kreitman, R.J., Stetler-Stevenson, M., Margulies, I., Noel, P., Fitzgerald, D.J., Wilson, W.H., Pastan, I. J. Clin. Oncol. (2009) [Pubmed]
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Kreitman, R.J. Curr. Pharm. Des. (2009) [Pubmed]
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. Kreitman, R.J. BioDrugs (2009) [Pubmed]
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Kreitman, R.J., Hassan, R., Fitzgerald, D.J., Pastan, I. Clin. Cancer Res. (2009) [Pubmed]
Approach to the patient after relapse of hairy cell leukemia. Kreitman, R.J., Fitzgerald, D.J., Pastan, I. Leuk. Lymphoma (2009) [Pubmed]
Immunotoxins in the treatment of refractory hairy cell leukemia. Kreitman, R.J., Pastan, I. Hematol. Oncol. Clin. North Am. (2006) [Pubmed]
BL22 and lymphoid malignancies. Kreitman, R.J., Pastan, I. Best. Pract. Res. Clin. Haematol (2006) [Pubmed]
Immunotoxins for targeted cancer therapy. Kreitman, R.J. AAPS. J (2006) [Pubmed]
Immunotoxins in the treatment of hematologic malignancies. Kreitman, R.J., Pastan, I. Curr. Drug. Targets (2006) [Pubmed]
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. Kreitman, R.J., Squires, D.R., Stetler-Stevenson, M., Noel, P., FitzGerald, D.J., Wilson, W.H., Pastan, I. J. Clin. Oncol. (2005) [Pubmed]
Recombinant immunotoxins for the treatment of haematological malignancies. Kreitman, R.J. Expert. Opin. Biol. Ther (2004) [Pubmed]
Confirmation and prevention of targeted toxicity by a recombinant fusion toxin. Kreitman, R.J. Mol. Cancer Ther. (2004) [Pubmed]
Recombinant toxins for the treatment of cancer. Kreitman, R.J. Curr. Opin. Mol. Ther. (2003) [Pubmed]
Immunobiological treatments of hairy-cell leukaemia. Kreitman, R.J., Pastan, I. Best. Pract. Res. Clin. Haematol (2003) [Pubmed]
Recombinant fusion toxins for cancer treatment. Kreitman, R.J. Expert. Opin. Biol. Ther (2002) [Pubmed]
Targeted therapies - First International Congress. Kreitman, R.J. IDrugs (2002) [Pubmed]
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D.J., Pastan, I. N. Engl. J. Med. (2001) [Pubmed]
Chimeric fusion proteins--Pseudomonas exotoxin-based. Kreitman, R.J. Curr. Opin. Investig. Drugs (2001) [Pubmed]
Immunotoxins. Kreitman, R.J. Expert. Opin. Pharmacother (2000) [Pubmed]
Immunotoxins in cancer therapy. Kreitman, R.J. Curr. Opin. Immunol. (1999) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.